多肿瘤标志物蛋白芯片系统在鉴别良恶性胸腹腔积液中的价值

The value of multi-tumor markers protein chip diagnosis system in the differential diagnosis of benign and malignant pleural effusion and ascites

目的探讨多肿瘤标志物蛋白芯片(C12)系统诊断良、恶性胸腹腔积液的信度和效度。方法用C12系统检测128例良、恶性患者胸腹水中十二项肿瘤标志物的检测水平,并与传统的细胞学方法比较。结果恶性胸水组CEA、Ferrtin、CA153和CA125水平较良性胸水组明显升高,恶性腹水组CEA、Ferrtin、CA199、CA242和CA125水平较良性腹水组明显升高,差异均有统计学意义。不同的肿瘤引起的胸腹水所对应的敏感指标也不相同。在细胞学阳性、可疑和阴性情况下,C12检测的符合率分别为83.78%、81.82%和83.75。结论多肿瘤标志物检测有助于良、恶性胸腹水的鉴别诊断,与单一肿瘤指标检测相比,提高了肿瘤疾病诊断的敏感性和特异性。

Aim To explore the reliability and validity of C12 system for the differential diagnosis of benign and malignant pleural effusion and ascites. Methods The levels of twelve tumor markers of pleural effusion and ascites were measured. Meanwhile,the diagnostic criteria were compared with the cytology of pleural effusion and ascites. Results The levels of CEA, Ferrtin, CA153 and CA125 of malignant pleural effusion group were remarkably higher than those of the benign group（ P 〈 0.01 ）. The levels of CEA, Fen＇tin, CA199, CA242 and CA125 of malignant ascites group were remarkably higher than those of the benign group（ P 〈0.01 ）. Different cancers always have different tumor markers. The coincident rate of C12 system was 83.78% ,81.82% and 83.75% respectively when the result of cytology was positive, doubt and negative respectively. Conclusion Multi-Tumor Markers Protein Chip diagnosis System is helpful to the differential diagnosis of benign and malignant pleural effusion and aseites. Compared with the detection of single tumor marker, it can increase the diagnostic specificity of malignant pleural effusion and ascites.